Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes.

Gejl M, Søndergaard HM, Stecher C, Bibby BM, Møller N, Bøtker HE, Hansen SB, Gjedde A, Rungby J, Brock B

The Journal of clinical endocrinology and metabolism27 Apr 2012Cited by 64 (Europe PMC)

PMID22544917DOI10.1210/jc.2011-3456PepBankPUB-22544917

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialActivity measurement
In men with diabetes, exenatide did not alter overall myocardial glucose uptake versus placebo.
In plain wordsIn men with diabetes, exenatide did not change overall heart glucose uptake compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeMyocardial glucose uptake overall
Study
n = 8
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Overall, exenatide did not alter MGU.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Report a problemFND-2254491701
02HumanRandomized controlled trialActivity measurement
In men with diabetes, exenatide altered initial cardiomyocyte glucose clearance depending on insulin resistance.
In plain wordsIn men with diabetes, the effect of exenatide on heart cell glucose clearance depended on insulin resistance.
Peptide
Exenatide (exendin-4)
Outcome
MixedInitial cardiomyocyte glucose clearance
Study
n = 8
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
However, regression analysis revealed that exenatide altered initial clearance of glucose over the membrane of cardiomyocytes and MGU, depending on the level of insulin resistance (P = 0.017 and 0.010, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Report a problemFND-2254491702
03HumanRandomized controlled trialActivity measurement
In men with diabetes, exenatide altered myocardial glucose uptake depending on insulin resistance.
In plain wordsIn men with diabetes, the effect of exenatide on heart glucose uptake depended on insulin resistance.
Peptide
Exenatide (exendin-4)
Outcome
MixedMyocardial glucose uptake by insulin resistance
Study
n = 8
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
However, regression analysis revealed that exenatide altered initial clearance of glucose over the membrane of cardiomyocytes and MGU, depending on the level of insulin resistance (P = 0.017 and 0.010, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Report a problemFND-2254491703
04HumanRandomized controlled trialActivity measurement
In men with diabetes, exenatide increased myocardial blood flow.
In plain wordsIn men with diabetes, exenatide increased heart blood flow.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMyocardial blood flow
Study
n = 8
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Measurements
Myocardial blood flow, first value of reported change
0.73 ml/g · min
reported 'from' value
Myocardial blood flow, second value of reported change
0.85 ml/g · min
reported 'to' value, with exenatide
Source sentences
Summary
Exenatide increased MBF from 0.73 ± 0.094 to 0.85 ± 0.091 ml/g · min (P = 0.0056).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Report a problemFND-2254491704
05HumanRandomized controlled trialActivity measurement
In men with diabetes, exenatide increased C-peptide levels versus placebo.
In plain wordsIn men with diabetes, exenatide increased C-peptide levels compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseC-peptide levels
Study
n = 8
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Except for an increase in C-peptide levels, no differences in circulating hormones or metabolites were found.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Report a problemFND-2254491705
06HumanRandomized controlled trialActivity measurement
In men with diabetes, other circulating hormones or metabolites did not differ with exenatide versus placebo.
In plain wordsIn men with diabetes, other circulating hormones and metabolites did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeOther circulating hormones and metabolites
Study
n = 8
Comparator
Placebo
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Except for an increase in C-peptide levels, no differences in circulating hormones or metabolites were found.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a randomized, double-blinded, placebo-controlled crossover study in eight male, insulin-naive, type 2 diabetes mellitus patients without coronary artery disease.
Report a problemFND-2254491706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

CompletedPhase 2/3NCT00747968

The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET

University of Aarhusn = 8Feb 2010 to Mar 2011

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 30 Jun 2011

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.